Articles

Leading companies spotlight innovations in cataract and refractive surgery at the 43rd ESCRS Congress in Copenhagen

Artificial intelligence is quickly expanding the breadth and depth of information clinicians can interpret, Prof Uy said

At the ESCRS meeting, cataract surgeons can get familiar with BVI's Virtuoso platform and VirtuaLens' immersive VR IOL simulator

Alcon, Bausch + Lomb and Johnson & Johnson will debut new research findings during the European Society of Cataract and Refractive Surgeons Congress in Copenhagen, Denmark

Ahead of the ESCRS congress and iNovation day, we go behind the scenes with Ciliatech founder Philippe Sourdille, MD, and president Olivier Benoit

Prof Stanzel detailed new advancements in proliferative vitreoretinopathy and a hyperaspheric IOL designed for patients with age-related macular degeneration

Dr Ramtohul's research uses electrophysiologic testing to study the retinal ganglion cells

The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD).

Presentation topics will include therapies for age-related macular degeneration, X-linked retinitis pigmentosa and other retinal pathologies

Jeremiah Tao, MD, FACS, used his Egyptian Ophthalmological Society keynote to explore complex and costly challenges in oculofacial surgery

Clinical leaders including Susan Schneider, MD; Lejla Vajzovic, MD; and Harvey Uy, MD, will share new clinical findings

An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration

Where to find members of our editorial board at this year's European Society of Retina Specialists Congress

Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France

New support offers a streamlined experience for surgeons and patients

The clinical support system integrates artificial intelligence into OCT interpretation workflow

Patients with higher exposure to nature and green spaces were significantly less likely to experience dry eye, investigators reported

AMD treatment may become unrecognisable as gene therapies evolve

The province's public health insurance scheme, Régie de l’assurance maladie du Québec (RAMQ), covers faricimab for three indications

A 12-month follow-up indicated no dose limiting toxicity and no ocular or systemic adverse effects

Every day brings a new challenge for surgeons in low-resource areas and conflict zones

Salvation of ocular tissues and visual acuity are dependent on early diagnosis, investigators emphasised

Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond

New financing will support the company's lead retinitis pigmentosa programme, among other projects

Consistent trends across prevalence, incidence, odds and time-to-event models suggest ocular mitochondrial disease may indicate neurodegenerative risk

Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries

An ophthalmologic examination revealed bilateral anterior uveitis, though the patient had no ocular complaints at presentation

João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases

The transaction is anticipated to close in 6 to 12 months subject to customary closing conditions and regulatory approval

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment